Genmab — Maj 2015
-
den burde nok have ventet lidt længere før den blev åbnet, men har ikke fået investeret i en vinkælder endnu, det må Jan Winkel lige hjælpe mig med
-
http://www.marketwatch.com/story/the-stocks-to-own-for-the-biotech-buyout-frenzy-2015-05-12?page=1 lidt anbefalinger af biotech, og hvorfor opkøbene kommer til at fortsætte
-
Elutuzumab phase III misser primært endpoint så vidt jeg kan se
-
http://abstracts.asco.org/156/AbstView_156_147696.html TF er for tidlig at konkludere på. Men ingen koagulations issue !
-
http://abstracts.asco.org/156/AbstView_156_144025.html det var HR jeg kiggede . Det var forkert
-
Men syntes ikke data er særlig gode. PFS ca. 19 måneder for ELD mod 14 for LD alene
-
men stadig meget høj hasard ratio for Elotuzumab både med revlimid og i velcade studiet. Jeg er ikke omponeret af Elo
-
Elo med velcade: http://abstracts.asco.org/156/AbstView_156_144027.html ikke det vilde heller
-
Only 1 pt (MOR202 0.15 mg/kg q2w) generated a transient anti-drug antibody response to MOR202.
-
-
http://abstracts.asco.org/156/AbstView_156_151048.html Arzerra Idelalisib med pæn forøgelse af effekt med idelalisib.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind